{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:56:13Z","timestamp":1790834173794,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02769-7","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T09:02:11Z","timestamp":1704877331000},"page":"1062-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ralinepag Phase\u00a0II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-4990","authenticated-orcid":false,"given":"Joan","family":"Barber\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Klings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Risti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Solum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isil","family":"Saib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"4","key":"2769_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903\u201375.","journal-title":"Eur Respir J"},{"issue":"2","key":"2769_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Circulation. 2010;122(2):164\u201372.","journal-title":"Circulation"},{"issue":"5","key":"2769_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D'Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2769_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12137","volume":"12","author":"PM Hendriks","year":"2022","unstructured":"Hendriks PM, Staal DP, van de Groep LD, et al. The evolution of survival of pulmonary arterial hypertension over 15\u00a0years. Pulm Circ. 2022;12(4):e12137.","journal-title":"Pulm Circ"},{"key":"2769_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","volume":"120","author":"LH Clapp","year":"2015","unstructured":"Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015;120:56\u201371.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2769_CR6","unstructured":"Adams J, Whittle B, Shen L, Patel J, Clapp LH. Potency, selectivity, and comparative platelet and vascular activity of ralinepag acting on prostacyclin receptors in human tissues. In: 6th World Symposium on Pulmonary Hypertension; February 27\u2013March 1, 2018; Nice, France."},{"issue":"suppl_1","key":"2769_CR7","doi-asserted-by":"publisher","first-page":"ehy563","DOI":"10.1093\/eurheartj\/ehy563.3022","volume":"39","author":"J Adams","year":"2018","unstructured":"Adams J, Blackburn A, Parsley E, Tang Y, King C, Grundy J. 3022 Relative bioavailability and pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet oral formulation and the effect of food and gender in healthy human subjects. Eur Heart J. 2018;39(suppl_1):ehy563-3022.","journal-title":"Eur Heart J"},{"issue":"2","key":"2769_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020922814","volume":"10","author":"JS Grundy","year":"2020","unstructured":"Grundy JS, King CD, Adams JW, Cabell CH. Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers. Pulm Circ. 2020;10(2):1\u201313.","journal-title":"Pulm Circ"},{"issue":"4","key":"2769_CR9","doi-asserted-by":"publisher","first-page":"1901030","DOI":"10.1183\/13993003.01030-2019","volume":"54","author":"F Torres","year":"2019","unstructured":"Torres F, Farber H, Risti\u0107 A, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase\u00a02 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019;54(4):1901030.","journal-title":"Eur Respir J"},{"key":"2769_CR10","doi-asserted-by":"crossref","unstructured":"Adams J, Morgan M, Unett D, Whittle B. Pharmacokinetics and efficacy of ralinepag (APD811) in rats and humans. European Respiratory Society; September 9\u201313, 2017; Milan, Italy.","DOI":"10.1183\/1393003.congress-2017.OA4662"},{"key":"2769_CR11","doi-asserted-by":"crossref","unstructured":"Grundy J, Blackburn A, Parsley E, Tang Y, King C, Adams J. Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet. European Respiratory Soc; September 15\u201319, 2018; Paris, France.","DOI":"10.1183\/13993003.congress-2018.PA3037"},{"issue":"4","key":"2769_CR12","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.healun.2019.01.504","volume":"38","author":"J Grundy","year":"2019","unstructured":"Grundy J, Blackburn A, Tang Y, King C, Adams J. Clinical pharmacokinetic performance of a ralinepag extended-release tablet. J Heart Lung Transplant. 2019;38(4):S207\u20138.","journal-title":"J Heart Lung Transplant"},{"key":"2769_CR13","unstructured":"Preston I, Adams J, Turner S, Christopher R. Safety and pharmacokinetics of ralinepag (APD811) in healthy adult subjects. Pulmonary Hypertension Professional Network Symposium; October 5\u20137, 2017; Bethesda, MD."},{"issue":"26","key":"2769_CR14","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"142","key":"2769_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1183\/16000617.0085-2016","volume":"25","author":"O Sitbon","year":"2016","unstructured":"Sitbon O, Gaine S. Beyond a single pathway: combination therapy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):408\u201317.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"2769_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","volume":"18","author":"M Burks","year":"2018","unstructured":"Burks M, Stickel S, Gali\u00e8 N. Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs. 2018;18(4):249\u201357.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"2769_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"2769_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","volume":"43","author":"AE Frost","year":"2005","unstructured":"Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. 2005;43(1):36\u20139.","journal-title":"Vascul Pharmacol"},{"issue":"25","key":"2769_CR19","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385(25):2361\u201376.","journal-title":"N Engl J Med"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eplepsyres.2016.10.020","volume":"129","author":"BE Gidal","year":"2017","unstructured":"Gidal BE, Clark AM, Anders B, Gilliam F. The application of half-life in clinical decision making: comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy Res. 2017;129:26\u201332.","journal-title":"Epilepsy Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02769-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:14:07Z","timestamp":1708452847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02769-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02769-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joan Barber\u00e0 is a consultant and speaker for Janssen-Cilag, Merck Sharp & Dome and Ferrer, consultant for Acceleron Pharma, and has received grants from Janssen-Cilag, Merck Sharp & Dome and Ferrer. Pavel Jansa has received fees and grants from Janssen Pharmaceutical Companies of Johnson and Johnson, AOP Orphan, United Therapeutics, and Merck Sharp & Dohme. He has served as advisory boards member for Janssen Pharmaceutical Companies of Johnson and Johnson, AOP Orphan, and Merck Sharp & Dohme. Elizabeth Klings receives research support from United Therapeutics, Novartis, Bayer, Novo Nordisk\/FORMA. She was an advisory board member for Vertex and Global Blood Therapeutics\/Pfizer. She is the member of the safety review committee for a phase\u00a01 trial for CSL Behring. Arsen Risti\u0107 and Anne Keogh have nothing to disclose. Namita Sood is a member of a speaker bureau for Bayer Pharmaceuticals and was a site PI for ADVANCE. Derek Solum, Youlan Rao, Rob Grover, and Isil Saib are employees of United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Written informed consent was obtained from all study subjects, and protocols were approved by the institutional review board at each participating study site. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. A full list of the committees at each study site can be found in the supplement; the central IRB was Western Institutional Review Board (WIRB), which has since updated their name to WCG IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}